Cyclo Therapeutics (NASDAQ:CYTH) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapies for rare and genetic diseases. Leveraging proprietary cyclodextrin technology, the company focuses on addressing disorders with significant unmet medical needs, including Niemann-Pick disease type C (NPC). Its lead product candidate, Trappsol® Cyclo, is a hydroxypropyl-β-cyclodextrin formulation designed to reduce cholesterol accumulation and support neurological function in NPC patients.
In addition to NPC, Cyclo Therapeutics is exploring the therapeutic potential of its cyclodextrin platform in other neurodegenerative conditions and lysosomal storage disorders. The company’s research initiatives encompass preclinical studies and early-stage clinical trials aimed at expanding the application of cyclodextrin compounds. By partnering with academic institutions, patient advocacy groups, and clinical research organizations, Cyclo Therapeutics aims to accelerate the development timeline and broaden access to its pipeline candidates.
Founded in 1994 and headquartered in Glen Rock, New Jersey, Cyclo Therapeutics operates research and manufacturing facilities in both the United States and Europe. This transatlantic presence supports scalable production of cyclodextrin formulations under stringent regulatory standards, with a focus on quality control and supply chain resilience. The company has engaged with European regulatory authorities and expert clinical sites to advance its pivotal trials, reflecting a global commitment to serving patient populations across multiple regions.
Cyclo Therapeutics is led by Chief Executive Officer Bart M. Toro, who brings over two decades of experience in biotechnology and orphan drug development. The executive team includes seasoned professionals in clinical development, regulatory affairs, and manufacturing, all working together to navigate the complex landscape of rare disease therapeutics. Guided by a patient-centric mission, the leadership is committed to delivering transformational treatments and improving outcomes for individuals living with debilitating genetic conditions.
